Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide analogues as novel treatments for Alzheimer's and Parkinson's disease

Biomedical and Life Sciences

Electronic data

Review_Cardiovasc_Endocrin_2016
Rights statement: Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Accepted author manuscript, 535 KB, PDF document
Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License

Text available via DOI:

https://doi.org/10.1097/XCE.0000000000000087
Final published version

View graph of relations

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide analogues as novel treatments for Alzheimer's and Parkinson's disease. / Hölscher, Christian.
In: Cardiovascular Endocrinology , Vol. 5, No. 3, 01.09.2016, p. 93-98.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Bibtex

@article{66e4f996a545489da4950e47d0a9b3a6,

title = "Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide analogues as novel treatments for Alzheimer's and Parkinson's disease",

abstract = "Type 2 diabetes is a risk factor for developing chronic neurodegenerative disorders such as Alzheimer's disease (AD) or Parkinson's disease (PD). The underlying mechanism appears to be insulin desensitization in the brain. A range of glucagon-like peptide 1 (GLP-1) mimetics and glucose-dependent insulinotropic polypeptide (GIP) analogues initially designed to treat diabetes protected transgenic animals that model AD and toxin-based animal models of PD. Novel dual GLP-1/GIP analogues also show good neuroprotective effects. On the basis of these findings, first clinical trials have been conducted. In a pilot study on patients with AD, the GLP-1 analogue liraglutide showed good protective effects in 18 F-fluorodeoxyglucose (18 F-FDG)-PET brain imaging. It was found that the disease-related decay of brain activity had been completely stopped by the drug. In a pilot study in patients with PD, the GLP-1 mimetic exendin-4 showed good protection from motor and cognitive impairments. These results demonstrate the potential of developing disease-modifying treatments for AD and PD.",

author = "Christian H{\"o}lscher",

year = "2016",

month = sep,

day = "1",

doi = "10.1097/XCE.0000000000000087",

language = "English",

volume = "5",

pages = "93--98",

journal = "Cardiovascular Endocrinology ",

issn = "2162-688X",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide analogues as novel treatments for Alzheimer's and Parkinson's disease

AU - Hölscher, Christian

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Type 2 diabetes is a risk factor for developing chronic neurodegenerative disorders such as Alzheimer's disease (AD) or Parkinson's disease (PD). The underlying mechanism appears to be insulin desensitization in the brain. A range of glucagon-like peptide 1 (GLP-1) mimetics and glucose-dependent insulinotropic polypeptide (GIP) analogues initially designed to treat diabetes protected transgenic animals that model AD and toxin-based animal models of PD. Novel dual GLP-1/GIP analogues also show good neuroprotective effects. On the basis of these findings, first clinical trials have been conducted. In a pilot study on patients with AD, the GLP-1 analogue liraglutide showed good protective effects in 18 F-fluorodeoxyglucose (18 F-FDG)-PET brain imaging. It was found that the disease-related decay of brain activity had been completely stopped by the drug. In a pilot study in patients with PD, the GLP-1 mimetic exendin-4 showed good protection from motor and cognitive impairments. These results demonstrate the potential of developing disease-modifying treatments for AD and PD.

AB - Type 2 diabetes is a risk factor for developing chronic neurodegenerative disorders such as Alzheimer's disease (AD) or Parkinson's disease (PD). The underlying mechanism appears to be insulin desensitization in the brain. A range of glucagon-like peptide 1 (GLP-1) mimetics and glucose-dependent insulinotropic polypeptide (GIP) analogues initially designed to treat diabetes protected transgenic animals that model AD and toxin-based animal models of PD. Novel dual GLP-1/GIP analogues also show good neuroprotective effects. On the basis of these findings, first clinical trials have been conducted. In a pilot study on patients with AD, the GLP-1 analogue liraglutide showed good protective effects in 18 F-fluorodeoxyglucose (18 F-FDG)-PET brain imaging. It was found that the disease-related decay of brain activity had been completely stopped by the drug. In a pilot study in patients with PD, the GLP-1 mimetic exendin-4 showed good protection from motor and cognitive impairments. These results demonstrate the potential of developing disease-modifying treatments for AD and PD.

U2 - 10.1097/XCE.0000000000000087

DO - 10.1097/XCE.0000000000000087

M3 - Journal article

VL - 5

SP - 93

EP - 98

JO - Cardiovascular Endocrinology

JF - Cardiovascular Endocrinology

SN - 2162-688X

IS - 3

ER -

Research

Electronic data

Links

Text available via DOI: